| P/E (FY) | 20.8 | Sales (TTM) | JPY 496.83B |
| Earnings (TTM) | JPY 67.04B | ROE | 7.69% |
| Net Margin | 13.49% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 8.72% | Sales Growth 3Y | 7.64% |
Kyowa Kirin Co. researches, develops, manufactures, and markets pharmaceuticals across Japan, the Americas, Europe, Asia, and internationally. Its products include Ziftomenib, an oral menin inhibitor for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, and Lumicef for palmoplantar pustulosis. The company also develops late-stage candidates such as rocatinlimab for atopic dermatitis, infigratinib for achondroplasia, and tivozanib for diabetic macular edema and age-related macular degeneration.
| Market Cap | $8.53B | Trading Days | 4014 |
| 52W High | 2912.00 |
| 52W Low | 2109.00 |
| % Off High | −8.62% |
| YTD | 6.77% | 1Y | 6.12% |
| 3Y | 3.87% | 5Y | −20.71% |
| 10Y | 68.48% | Since incept. (ann.) | 8.12% |
| Ann. Volatility (1Y) | 33.96% | Ann. Volatility (3Y) | 30.84% |
| Sharpe (1Y) | 0.37 | Sharpe (3Y) | 0.20 |
| Max Drawdown (1Y) | −24.99% | Max Drawdown (3Y) | −38.00% |
| Beta (3Y, vs SPY) | 0.31 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AVTR | Avantor, Inc. | $8.48B | — |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| 4523.T | Eisai Co., Ltd. | $8.46B | 24.6 |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.73B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| RGEN | REPLIGEN CORP | $8.20B | 169.0 |
| GKOS | GLAUKOS Corp | $8.89B | — |
| APGE |
| Apogee Therapeutics, Inc. |
| $8.14B |
| — |
